Touw Ketrija, Ringus Daina L, Hubert Nathaniel, Wang Yunwei, Leone Vanessa A, Nadimpalli Anuradha, Theriault Betty R, Huang Yong E, Tune Johnathan D, Herring Paul B, Farrugia Gianrico, Kashyap Purna C, Antonopoulos Dionysios A, Chang Eugene B
Department of Medicine, University of Chicago, Chicago, Illinois.
Department of Surgery, University of Chicago, Chicago, Illinois.
Physiol Rep. 2017 Mar;5(6). doi: 10.14814/phy2.13182.
Chronic diseases arise when there is mutual reinforcement of pathophysiological processes that cause an aberrant steady state. Such a sequence of events may underlie chronic constipation, which has been associated with dysbiosis of the gut. In this study we hypothesized that assemblage of microbial communities, directed by slow gastrointestinal transit, affects host function in a way that reinforces constipation and further maintains selection on microbial communities. In our study, we used two models - an opioid-induced constipation model in mice, and a humanized mouse model where germ-free mice were colonized with stool from a patient with constipation-predominant irritable bowel syndrome (IBS-C) in humans. We examined the impact of pharmacologically (loperamide)-induced constipation (PIC) and IBS-C on the structural and functional profile of the gut microbiota. Germ-free (GF) mice were colonized with microbiota from PIC donor mice and IBS-C patients to determine how the microbiota affects the host. PIC and IBS-C promoted changes in the gut microbiota, characterized by increased relative abundance of and in both models. PIC mice exhibited decreased luminal concentrations of butyrate in the cecum and altered metabolic profiles of the gut microbiota. Colonization of GF mice with PIC-associated mice cecal or human IBS-C fecal microbiota significantly increased GI transit time when compared to control microbiota recipients. IBS-C-associated gut microbiota also impacted colonic contractile properties. Our findings support the concept that constipation is characterized by disease-associated steady states caused by reinforcement of pathophysiological factors in host-microbe interactions.
当导致异常稳态的病理生理过程相互强化时,慢性病就会出现。这样一系列事件可能是慢性便秘的基础,而慢性便秘与肠道微生物群失调有关。在本研究中,我们假设由胃肠道缓慢转运引导的微生物群落组合以一种强化便秘并进一步维持对微生物群落选择的方式影响宿主功能。在我们的研究中,我们使用了两种模型——小鼠阿片类药物诱导的便秘模型,以及一种人源化小鼠模型,即无菌小鼠用人类便秘型肠易激综合征(IBS-C)患者的粪便进行定殖。我们研究了药理学(洛哌丁胺)诱导的便秘(PIC)和IBS-C对肠道微生物群结构和功能特征的影响。将无菌(GF)小鼠用来自PIC供体小鼠和IBS-C患者的微生物群进行定殖,以确定微生物群如何影响宿主。PIC和IBS-C促进了肠道微生物群的变化,其特征是在两种模型中 和 的相对丰度增加。PIC小鼠盲肠中丁酸盐的腔内浓度降低,肠道微生物群的代谢谱发生改变。与对照微生物群受体相比,用PIC相关小鼠盲肠或人类IBS-C粪便微生物群对GF小鼠进行定殖显著增加了胃肠道转运时间。IBS-C相关的肠道微生物群也影响结肠收缩特性。我们的研究结果支持这样一种概念,即便秘的特征是由宿主-微生物相互作用中病理生理因素的强化导致的与疾病相关的稳态。